Clinical trials: Frontline
High-Risk de Novo Multiple Myeloma
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
The goal of this Phase 2, open-label, multicenter, non-randomized pilot study is to evaluate the efficacy (in terms of MRD negative CR rate after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and…
- Trial name
- GEM-TECTAL (NCT05849610)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 10 sites in Spain
- Volunteers
- 30 people
- Sponsor
- PETHEMA Foundation
Postpartum Hemorrhage, Neonatal Asphyxia
Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program Evaluation
The study aims are to evaluate the impact of supportive follow-up strategies for a novel twinned training and capacity-sustaining program among frontline health workers (providers) attending facility-based births in remote and…
- Trial name
- NCT03254628
- Testing
- Helping Mothers Survive - Bleeding After Birth training, Helping Babies Breathe, Mentor
- Volunteers
- 3,440 people
- Sponsor
- Jhpiego
Multiple Myeloma
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side…
- Trial name
- NCT00843310
- Testing
- Lenalidomide (Revlimid), Melphalan, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
CANCER, BRAEST CANCER
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
Experimental population:Advanced first-line HR+, HER2 metastatic breast cancer patients Research endpoint: Main research endpoint: PFS evaluated by researchers (according to RECIST 1.1 standard) Secondary study endpoint…
- Conditions
- CANCER, BRAEST CANCER, Late Frontline
- Trial name
- NCT06495515
- Testing
- Dalpiciclib，Toremifen
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of veliparib when given together with or without cisplatin and etoposide and to see how well they work in treating patients with extensive stage small cell…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma
- Trial name
- NCT01642251
- Testing
- Cisplatin, Etoposide, Veliparib
- Where
- 428 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Study to support the mental and physical well-being of US health care workers during the COVID-19 pandemic and ensure high-quality care for patients through Stress First Aid.
- Trial name
- COVER-HCW (NCT04723576)
- Testing
- Stress First Aid
- Where
- 2 sites in United States
- Volunteers
- 7,444 people, healthy volunteers welcome
- Sponsor
- RAND
Burnout, Healthcare Workers, Workplace Violence
Burnout and Safety Assessment in Home Hospital Versus Brick-and-Mortar Hospital
The goal of this observational study is to learn about burnout and workplace violence among frontline clinicians working in Home Hospital programs compared with traditional brick-and-mortar hospitals.
- Trial name
- BSAFE (NCT07773168)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Brigham and Women's Hospital
Chronic Myelocytic Leukemia
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
This study is conducted in patients with newly diagnosed CP CML (Chronic Phase Chronic Myeloid Leukemia) who have achieved EMR (< 10% IS BCR-ABL) at 3 months after first line treatment with dasatinib.
- Trial name
- NCT04150471
- Testing
- RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Seoul St. Mary's Hospital
Acute Myeloid Leukemia
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy.
- Trial name
- NCT06930352
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Uma Borate
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00054158
- Testing
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Burnout, Psychological, Anxiety
The Effect of Demographic, Mental, and Physical Activity Profiles Towards Burnout in Frontline Healthcare Workers Facing COVID-19 Pandemics in Dr. Soetomo General Hospital Surabaya
This was a randomized controlled trial study to measure the effect of intervention of Zumba dance towards psychological and biological markers in hospital residents managing COVID-19 patients
- Trial name
- NCT05246124
- Testing
- Zumba dance exercise
- Where
- Indonesia
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Follicular Lymphoma
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component.
- Trial name
- NCT05551936
- Testing
- Bendamustine, Rituximab, Tazemetostat
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vaishalee Kenkre
Child Malnutrition, Breastfeeding
Impact of Behavior Change Communications and Market-based Approach to Delivering Micronutrient Powders on Stunting, Infant Feeding Practices and Anemia in Bangladesh
This complex evaluation of a large-scale program uses a cluster-randomized design where 20 geographic clusters (subdistricts) were randomized to study two sets of interventions.
- Conditions
- Child Malnutrition, Breastfeeding, Complementary Feeding, Childhood Anemia
- Trial name
- NCT01678716
- Testing
- EHC + BCC, Micronutrient powders, Mass media
- Where
- Bangladesh
- Volunteers
- 8,800 people, healthy volunteers welcome
- Sponsor
- International Food Policy Research Institute
Peripheral T-cell Lymphoma
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT04569032
- Testing
- brentuximab vedotin, cyclophosphamide, doxorubicin
- Where
- 63 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Covid19
Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers
Rationale: Early in the covid-19 pandemic, it was unclear whether and how individuals and populations would develop protective and enduring immunity against SARS-CoV-2, either after infection or vaccination.
- Trial name
- NCT05049187
- Where
- India
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Multiple Myeloma
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance…
- Trial name
- AURIGA (NCT03901963)
- Testing
- Daratumumab, Lenalidomide
- Where
- 73 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Pancreatic Adenocarcinoma
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy for advanced disease.
- Trial name
- RiLEY (NCT06896188)
- Testing
- Retifanlimab, Chemotherapy, 9-ING-41
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Anwaar Saeed
Post-Traumatic Stress Disorder, Adjustment Disorders
MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders
The purpose of this study is to assess the safety and efficacy of MDMA-Assisted Therapy on Frontline Health Care Workers and First Responders suffering from symptoms of Post-Traumatic Stress.
- Trial name
- NCT05455996
- Testing
- MDMA
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nautilus Sanctuary
Chronic Lymphocytic Leukemia, Leukemia
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn more about the characteristics of CLL, including genes and chromosome abnormalities and proteins expressed by the leukemia cells, which may help doctors predict if patients who…
- Trial name
- NCT00759798
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- M.D. Anderson Cancer Center
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who responded to initial treatment used to reduce a cancer (front-line therapy) but have residual…
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- MERIT (NCT02649387)
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic